Gretchen E. Bollar

Gretchen E. Bollar

Auto-generated profile, based on publicly available information

Gretchen E. Bollar

Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham , Birmingham, AL

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Infection and Immunity
Verified
Journal Article
Closed access
GBGretchen E. Bollar
Gretchen E. Bollar
JKJohnathan D. Keith
Johnathan D. Keith
AOAshley M. Oden
Ashley M. Oden
MKMegan R. Kiedrowski
Megan R. Kiedrowski
SBSusan E. Birket
Susan E. Birket
Cystic fibrosis (CF) disease is characterized by lifelong infections with pathogens such as Staphylococcus aureus , leading to eventual respiratory failure. Small colony variants (SCVs) of S. aureus have been linked to worse clinical outcomes for people with CF.

30 October 2024 in The American Journal of Pathology
Verified
Journal Article
Closed access
GBGretchen E. Bollar
Gretchen E. Bollar
JKJohnathan D. Keith
Johnathan D. Keith
DSDenise D. Stanford
Denise D. Stanford
AOAshley M. Oden
Ashley M. Oden
SRS. Vamsee Raju
S. Vamsee Raju
SBSusan E. Birket
Susan E. Birket

5 December 2025 in Water Research
Verified
Journal Article
Open access
GBGretchen E. Bollar
Gretchen E. Bollar
AKAnthony M. Kocur
Anthony M. Kocur
JAJoshua M. Allen
Joshua M. Allen
ACAmy A. Cuthbertson
Amy A. Cuthbertson
TATareq Aziz
Tareq Aziz
SRSusan D. Richardson
Susan D. Richardson
Bottled water consumption has increased globally at a tremendous rate, however, little is known about levels of disinfection by-products (DBPs) in bottled water beyond the regulated trihalomethanes (THMs), haloacetic acids (HAAs), and bromate. This is important because many bottled waters are sourced from tap water. Using gas chromatography-mass spectrometry, we quantified 64 regulated and priority, unregulated DBPs in 10 popular brands of bottled water, including 50 toxicologically important, unregulated DBPs not measured in previous studies. Several priority, unregulated DBPs were found in bottled water for the first time, including dibromoacetonitrile, chloroacetonitrile, dichloroacetamide, trichloronitromethane, dichloroacetaldehyde, 1,1-dibromopropanone, and 1,1,1-trichloropropanone. Dibromoacetonitrile was present in two Grocery Brand bottled waters, up to 0.2 μg/L, and is particularly important because it is highly cytotoxic, genotoxic, and carcinogenic. Total organic halogen (TOX) was also measured in bottled waters for the first time. All bottled waters contained measurable TOX, with highest TOCl levels in Grocery/Name Brands (up to 31.4 μg/L) and highest TOBr levels in a Name Brand water (up to 7.0 μg/L). A surprising finding was the presence of HAAs and chloroform in one of the Designer Brands, which is supposed to be treated with UV disinfection only. THMs and HAAs were found at the highest levels (0.01-12.4 µg/L), with other priority, unregulated DBPs present at ng/L levels when detected. However, while all bottled waters (even untreated spring waters) contained DBPs, they were present at levels significantly lower than typically found in tap water. For example, total DBP levels ranged from 0.01-22.4 µg/L (mean of 2.6 µg/L) in bottled water, compared to 47.3 µg/L and 52.2 µg/L for chloraminated tap water and other tap waters treated with chlorine and other disinfectants, respectively. Also, fewer DBPs were detected in the bottled waters (3 on average vs. 37 in the tap water). The rank order of lowest to highest mean DBP levels followed: Designer Brands < Grocery Brands < Name Brands (0.6, 3.1, and 3.7 µg/L, respectively). Grocery Brands and Name Brands had higher numbers of DBPs compared to Designer Brands. Brands sourced from spring water generally showed lower overall DBP levels than those labeled as purified. DBP levels varied dramatically with lot number (from the same brand), with large variability in both the number of DBPs detected and concentrations. Finally, two grocery brands, which were purified tap waters, had significantly higher calculated cytotoxicity than other bottled waters sampled, with 43x and 83x the average levels of other bottled waters, but bottled waters overall had quite low calculated cytotoxicity compared to tap water.

30 October 2024 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
GBGretchen E Bollar
Gretchen E Bollar
KSKendall M Shaffer
Kendall M Shaffer
JKJohnathan D Keith
Johnathan D Keith
AOAshley M Oden
Ashley M Oden
ADAlexander E Dowell
Alexander E Dowell
SBSusan E Birket
Susan E Birket
Background: Ivacaftor exhibits anti-staphylococcal properties but does not clear Staphylococcus aureus from the lungs of people with cystic fibrosis (pwCF). We assessed whether exposure to therapeutic concentrations of ivacaftor could allow S. aureus to form small colony variants (SCVs), a phenotype commonly associated with bacterial persistence. Methods: Humanized G551D-CFTR (hG551D) rats were treated with ivacaftor for 7 days. Concentrations in the plasma, epithelial lining fluid and lung tissue lysate were measured using LC-MS/MS. Survival of S. aureus during ivacaftor treatment was assessed in an hG551D rat model of lung infection. S. aureus adaptation to therapeutic concentrations of ivacaftor was investigated in vitro by serial passage in the presence of 10 µM ivacaftor. Bacterial survival in the presence of antimicrobials was evaluated using growth curves and density assays. Results: Ivacaftor plasma concentrations of treated hG551D rats reached 3.488 ± 1.118 µM, with more variable concentrations in the epithelial lining fluid and lung tissue lysate. During S. aureus infection, ivacaftor-treated hG551D rats returned similar numbers of bacteria from the lung, compared with vehicle-treated controls. Exposure of S. aureus to ivacaftor in vitro led to the formation of ivacaftor-tolerant SCVs with an unstable phenotype and increased antibiotic tolerance. Conclusions: Treatment with ivacaftor did not alter S. aureus burden in the cystic fibrosis rat and led to the formation of tolerant SCVs in vitro, suggesting that development of an SCV phenotype may allow S. aureus to persist in the cystic fibrosis lung during ivacaftor therapy.